Access cutting-edge gastric cancer treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Access gastric cancer specialists in Minneapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related gastric cancer treatment provided free
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy a
Sponsor: Daiichi Sankyo
Check if you qualify for this gastric cancer clinical trial in Minneapolis, MN
If you're searching for gastric cancer treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastric cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.